血液学の最新論文（2019年12月リリース分）New reports on Hematology
Leukemia
- Blood Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia patients treated in the ALFA0701 trial. Blood. 2019 Dec 27. pii: blood.2019003471. doi: 10.1182/blood.2019003471. Fournier E, Duployez N, Ducourneau B, Raffoux E, Turlure P, Caillot D, Thomas X, Marceau-Renaut A, Chantepie SP, Malfuson JV, Lemasle E, Cheok MH, Celli-Lebras K, Guerin E, Terré C, Lambert J, Pautas C, Dombret H, Castaigne S, Preudhomme C, Boissel N
- Blood Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study. Blood. 2019 Dec 26. pii: blood.2019002969. doi: 10.1182/blood.2019002969. Soverini S, Bavaro L, De Benedittis C, Martelli M, Iurlo A, Orofino N, Sica S, Sora F, Lunghi F, Ciceri F, Galimberti S, Baratè C, Bonifacio M, Scaffidi L, Castagnetti F, Gugliotta G, Albano F, Russo Rossi AV, Stagno F, Di Raimondo F, D'Adda M, Di Bona E, Abruzzese E, Binotto G, Sancetta R, Salvucci M, Capodanno I, Girasoli M, Coluzzi S, Attolico I, Musolino C, Calistri E, Annunziata M, Bocchia M, Stella S, Serra A, Errichiello S, Saglio G, Pane F, Vigneri PG, Mignone F, Laginestra MA, Pileri SA, Percesepe A, Tenti E, Rosti G, Baccarani M, Cavo M, Martinelli G
- Blood Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2019 Dec 26. pii: blood.2018884940. doi: 10.1182/blood.2018884940. Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Burke K, Covey T, Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, O'Brien S, Furman RR
- Blood Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2019 Dec 16. pii: blood.2019002140. doi: 10.1182/blood.2019002140. Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM
- Blood Beat pediatric ALL MRD: CD28 CAR T and transplant. 134(26):2333-2335 Ruella M, Locke FL
- Blood Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. 134(26):2361-2368 Curran KJ, Margossian SP, Kernan NA, Silverman LB, Williams DA, Shukla N, Kobos R, Forlenza CJ, Steinherz P, Prockop S, Boulad F, Spitzer B, Cancio MI, Boelens JJ, Kung AL, Szenes V, Park JH, Sauter CS, Heller G, Wang X, Senechal B, O'Reilly RJ, Riviere I, Sadelain M, Brentjens RJ
- Blood JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. 134(26):2388-2398 Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann JM, Agarwal AM, Clair P, Addada J, Lambert J, Salmon M, Gleich GJ, Cross NCP, Constantinescu SN, O'Hare T, Prchal JT, Deininger MW
- Blood Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia. 134(26):2414-2416 Duployez N, Willekens C, Plo I, Marceau-Renaut A, de Botton S, Fenwarth L, Boyer T, Huet G, Nibourel O, Rose C, Nelken B, Quesnel B, Preudhomme C
- Blood The curious incident of TdT-mediated mutations in AML. 134(25):2229-2231 Vassiliou GS
- Blood Terminal deoxynucleotidyl transferase promotes acute myeloid leukemia by priming FLT3-ITD replication slippage. 134(25):2281-2290 Borrow J, Dyer SA, Akiki S, Griffiths MJ
- Blood Molecular roulette: nucleophosmin mutations in AML are orchestrated through N-nucleotide addition by TdT. 134(25):2291-2303 Borrow J, Dyer SA, Akiki S, Griffiths MJ
- Blood Is There an Optimal Conditioning for Older Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation? Blood. 2019 Dec 11. pii: blood.2019003662. doi: 10.1182/blood.2019003662. Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta RS, Oran B, Popat U, Hosing C, Olson A, Daver N, Konopleva M, Champlin R
- Blood Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. 2019 Dec 11. pii: blood.2019002697. doi: 10.1182/blood.2019002697. Döhner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, Prior TW, Marcucci G, Jones D, Krauter J, Heuser M, Voso MT, Ottone T, Nomdedeu JF, Mandrekar SJ, Klisovic R, Wei AH, Sierra J, Sanz MA, Brandwein J, de Witte TM, Jansen JH, Niederwieser D, Appelbaum F, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Benner A, Pallaud C, Stone RM, Döhner H, Bloomfield CD
- Blood IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? Blood. 2019 Dec 10. pii: blood.2019000813. doi: 10.1182/blood.2019000813. Stanulla M, Cavé H, Moorman AV
- Blood Myeloid Cell-Targeted miR-146a Mimic Inhibits NF-kB-Driven Inflammation and Leukemia Progression in Vivo. Blood. 2019 Dec 5. pii: blood.2019002045. doi: 10.1182/blood.2019002045. Su YL, Wang X, Mann M, Adamus TP, Wang D, Moreira DF, Zhang Z, Ouyang C, He X, Zhang B, Swiderski PM, Forman SJ, Baltimore D, Li L, Marcucci G, Boldin M, Kortylewski M
- Blood Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL. Blood. 2019 Dec 3. pii: blood.2019001262. doi: 10.1182/blood.2019001262. Kwok M, Oldreive C, Rawstron AC, Goel A, Papatzikas G, Jones RE, Drennan S, Agathanggelou A, Sharma-Oates A, Evans P, Smith E, Dalal S, Mao J, Hollows R, Gordon N, Hamada M, Davies NJ, Parry H, Beggs AD, Munir T, Moreton P, Paneesha S, Pratt G, Taylor AMR, Forconi F, Baird DM, Cazier JB, Moss P, Hillmen P, Stankovic T
- Blood IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia. 134(24):2171-2182 González-García S, Mosquera M, Fuentes P, Palumbo T, Escudero A, Pérez-Martínez A, Ramírez M, Corcoran AE, Toribio ML
- Blood AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia. 134(24):2183-2194 Jiang Y, Hu T, Wang T, Shi X, Kitano A, Eagle K, Hoegenauer KA, Konopleva MY, Lin CY, Young NL, Nakada D
- Blood Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia. 134(23):2036-2045 Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Aimone P, Allepuz A, Quenet S, Hourcade-Potelleret F, Hertle S, Sosothikul D
- Br J Haematol Mucormycosis in children with haematological malignancies is a salvageable disease: a report from the Israeli Study Group of Childhood Leukemia. Br J Haematol. 2019 Dec 29. doi: 10.1111/bjh.16329. Elitzur S, Arad-Cohen N, Barg A, Litichever N, Bielorai B, Elhasid R, Fischer S, Fruchtman Y, Gilad G, Kapelushnik J, Kharit M, Konen O, Laor R, Levy I, Raviv D, Shachor-Meyouhas Y, Shvartser-Beryozkin Y, Toren A, Yaniv I, Nirel R, Izraeli S, Barzilai-Birenboim S
- Br J Haematol Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker. Br J Haematol. 2019 Dec 27. doi: 10.1111/bjh.16254. Kloos R, van der Sluis IM, Mastrobattista E, Hennink W, Pieters R, Verhoef JJ
- Br J Haematol Mutational features of myelodysplastic syndromes with Auer rods reveal them are more akin to acute myeloid leukemia. Br J Haematol. 2019 Dec 27. doi: 10.1111/bjh.16326. Huang H, Qin T, Xu Z, Shi Z, Li B, Pan L, Hu N, Qu S, Huang G, Gale RP, Xiao Z
- Br J Haematol Post-chimeric antigen receptor T-cell therapy haematopoietic stem cell transplantation for 52 cases with refractory/relapsed B-cell acute lymphoblastic leukaemia. Br J Haematol. 2019 Dec 23. doi: 10.1111/bjh.16339. Zhang Y, Chen H, Song Y, Tan X, Zhao Y, Liu X, Li Z, Yang F, Jiang M, Gao Z, Wu T
- Br J Haematol Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide. Br J Haematol. 2019 Dec 21. doi: 10.1111/bjh.16343. Bankar A, Korula A, Kulkarni UP, Devasia AJ, Na F, Lionel S, Abraham A, Balasubramanian P, Janet NB, Nair SC, S S, Jeyaseelan V, N J, Prasad J, George B, Mathews V
- Br J Haematol Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. Br J Haematol. 2019 Dec 19. doi: 10.1111/bjh.16345. Gribben JG
- Br J Haematol Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia. Br J Haematol. 2019 Dec 18. doi: 10.1111/bjh.16320. Nilsson MS, Hallner A, Brune M, Nilsson S, Thorén FB, Martner A, Hellstrand K
- Br J Haematol Megakaryocyte emperipolesis in B-lymphoblastic leukaemia. Br J Haematol. 2019 Dec 17. doi: 10.1111/bjh.16277. Gurney M, Krawczyk J, Paz Nuñez YE
- Br J Haematol Long-term outcome evaluation of medium/high risk acute lymphoblastic leukaemia children treated with or without cranial radiotherapy in the EORTC 58832 randomized study. Br J Haematol. 2019 Dec 13. doi: 10.1111/bjh.16337. Piette C, Suciu S, Bertrand Y, Uyttebroeck A, Vandecruys E, Plat G, Paillard C, Pluchart C, Sirvent N, Maurus R, Poirée M, Simon P, Ferster A, Hoyoux C, Mazingue F, Paulus R, Freycon C, Thomas C, Philippet P, Gilotay C, van der Werff Ten Bosch J, Rohrlich PS, Benoit Y
- Br J Haematol Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future. Br J Haematol. 2019 Dec 12. doi: 10.1111/bjh.16357. Hills RK
- Br J Haematol Twenty five years of UK trials in acute myeloid leukaemia: what have we learned? Br J Haematol. 2019 Dec 11. doi: 10.1111/bjh.16359. Burnett AK, Hills RK, Russell N
- Br J Haematol Mixed phenotype acute leukaemia with predominant myeloid blasts and a small subset of B/myeloid blasts shares the same mutation profile. Br J Haematol. 2019 Dec 11. doi: 10.1111/bjh.16325. Capitano M, Capo-Chichi JM, Minden MD, Chang H
- Br J Haematol AML – a signature disease in haematology. Br J Haematol. 2019 Dec 10. doi: 10.1111/bjh.16365. Hokland P
- Br J Haematol Changes in neurocognitive function and central nervous system structure in childhood acute lymphoblastic leukaemia survivors after treatment: a meta-analysis. Br J Haematol. 2019 Dec 10. doi: 10.1111/bjh.16279. Zhou C, Zhuang Y, Lin X, Michelson AD, Zhang A
- Br J Haematol The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol. 2019 Dec 10. doi: 10.1111/bjh.16355. Loke J, Malladi R, Moss P, Craddock C
- Br J Haematol Clonal hierarchy of main molecular lesions in acute myeloid leukaemia. Br J Haematol. 2019 Dec 10. doi: 10.1111/bjh.16341. Herudkova Z, Culen M, Folta A, Jeziskova I, Cerna J, Loja T, Tom N, Smejkal J, Semerad L, Dvorakova D, Mayer J, Racil Z
- Br J Haematol Acute promyelocytic leukaemia with myeloperoxidase-negative rectangular inclusions. Br J Haematol. 2019 Dec 10. doi: 10.1111/bjh.16363. Mo X, Chen H
- Br J Haematol The power and potential of integrated diagnostics in acute myeloid leukaemia. Br J Haematol. 2019 Dec 6. doi: 10.1111/bjh.16360. Haferlach T, Schmidts I
- Br J Haematol Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France. Br J Haematol. 2019 Dec 6. doi: 10.1111/bjh.16364. Garcia Spezza E, Brethon B, Petit A, Mazingue F, Gandemer V, Boissel N, Carausu L, Reguerre Y, Leverger G, Ducassou S
- Br J Haematol Checkpoint inhibitors in AML: are we there yet? Br J Haematol. 2019 Dec 6. doi: 10.1111/bjh.16358. Ghosh A, Barba P, Perales MA
- Br J Haematol Epigenetics of paediatric acute myeloid leukaemia. Br J Haematol. 2019 Dec 5. doi: 10.1111/bjh.16361. Jones L, McCarthy P, Bond J
- Br J Haematol Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia. Br J Haematol. 2019 Dec 5. doi: 10.1111/bjh.16261. Holtzman NG, El Chaer F, Baer MR, Ali O, Patel A, Duong VH, Sausville EA, Singh ZN, Koka R, Zou YS, Etemadi A, Emadi A
- Br J Haematol Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia. Br J Haematol. 2019 Dec 5. doi: 10.1111/bjh.16362. Ghannam J, Dillon LW, Hourigan CS
- Br J Haematol Identification of a novel TFG-FGFR1 fusion gene in an acute myeloid leukaemia patient with t(3;8)(q12;p11). Br J Haematol. 2019 Dec 4. doi: 10.1111/bjh.16294. Wang T, Wang Z, Zhang L, Wen L, Cai W, Yang X, Pan J, Ruan C, Wu D, Sun A, Chen S
- Br J Haematol Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL. Br J Haematol. 2019 Dec 3. doi: 10.1111/bjh.16306. Brown P, Zugmaier G, Gore L, Tuglus CA, von Stackelberg A
- Br J Haematol Bone marrow metastases mimicking acute leukaemia. 187(5):556 Chraïbi S, Vergé V, Micol JB
- Br J Haematol Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice. 187(5):615-626 Huguet F, Cayuela JM, Cambier N, Carpentier N, Tindel M, Violet I, Zunic P, Lascaux A, Etienne G; AdheRMC Investigators
- Haematologica Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the campus all network. Haematologica. 2019 Dec 26. pii: haematol.2019.231704. doi: 10.3324/haematol.2019.231704. Del Principe MI, Buzzatti E, Piciocchi A, Forghieri F, Bonifacio M, Lessi F, Imbergamo S, Orciuolo E, Rossi G, Fracchiolla N, Trappolini S, Neri B, Sarlo C, Zappasodi P, Dargenio M, Cefalo M, Irno-Consalvo MA, Conti C, Paterno G, De Angelis G, Sciumè M, Della Starza I, Venditti A, Foà R, Guarini AR
- Haematologica Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Haematologica. 2019 Dec 26. pii: haematol.2019.231027. doi: 10.3324/haematol.2019.231027. Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, Bloehdorn J, Hoechstetter M, Fischer K, Eichhorst B, Goede V, Hallek M, Döhner H, Rosenquist R, Ghia P, Stamatopoulos K, Stilgenbauer S
- Haematologica The novel L-nucleoside analogue, 5-Fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia. Haematologica. 2019 Dec 19. pii: haematol.2019.226795. doi: 10.3324/haematol.2019.226795. Bankar A, Siriwardena TP, Rizoska B, Rydergård C, Kylefjord H, Rraklli V, Eneroth A, Pinho P, Norin S, Bylund J, Moses S, Bethell R, Kavanagh S, Maclean N, Gronda M, Wang X, Hurren R, Minden MD, Targett-Adams P, Schimmer AD, Albertella M
- Haematologica Transcription factor 4 (TCF4) expression predicts clinical outcome in RUNX1 mutated and translocated acute myeloid leukemia. Haematologica. 2019 Dec 19. pii: haematol.2019.232827. doi: 10.3324/haematol.2019.232827. In 't Hout FEM, Gerritsen M, Bullinger L, van der Reijden BA, Huls G, Vellenga E, Jansen JH
- Haematologica Leukemia cells remodel marrow adipocytes via TRPV4-dependent lipolysis. Haematologica. 2019 Dec 19. pii: haematol.2019.225763. doi: 10.3324/haematol.2019.225763. Yang S, Lu W, Zhao C, Zhai Y, Wei Y, Liu J, Yu Y, Li Z, Shi J
- Haematologica Humanized zebrafish enhance human hematopoietic stem cell survival and promote acute myeloid leukemia clonal diversity. Haematologica. 2019 Dec 19. pii: haematol.2019.223040. doi: 10.3324/haematol.2019.223040. Rajan V, Melong N, Wong WH, King B, Tong RS, Mahajan N, Gaston D, Lund T, Rittenberg D, Dellaire G, Campbell CJV, Druley T, Berman JN
- Haematologica Cloning and characterization of a novel druggable fusion kinase in acute myeloid leukemia. Haematologica. 2019 Dec 2. pii: haematol.2019.237818. doi: 10.3324/haematol.2019.237818. Michel C, Mack EKM, Mais CN, Fritz LV, Wang Y, Jehn LB, Hühn SK, Simon C, Inselmann S, Marquardt A, Kremer J, Wollmer E, Sohlbach K, Neubauer A, Brendel CA, Haferlach C, Bange G, Burchert A
- Haematologica Are we ready to use precision medicine in chronic myeloid leukemia practice? 104(12):2327-2329 Kim DDH
- Haematologica DNA damage on the DOCK in FLT3-ITD-driven acute myeloid leukemia. 104(12):2330-2332 Pandey R, Kapur R
- Haematologica Fine tuning of p53 functions between normal and leukemic cells: a new strategy for the treatment of chronic lymphocytic leukemia. 104(12):2332-2334 Stankovic T
- Haematologica Clonal hematopoiesis and risk of acute myeloid leukemia. 104(12):2410-2417 Young AL, Tong RS, Birmann BM, Druley TE
- Haematologica Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells. 104(12):2429-2442 Ciardullo C, Aptullahoglu E, Woodhouse L, Lin WY, Wallis JP, Marr H, Marshall S, Bown N, Willmore E, Lunec J
- Haematologica Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. 104(12):2443-2455 Boudny M, Zemanova J, Khirsariya P, Borsky M, Verner J, Cerna J, Oltova A, Seda V, Mraz M, Jaros J, Jaskova Z, Spunarova M, Brychtova Y, Soucek K, Drapela S, Kasparkova M, Mayer J, Paruch K, Trbusek M
- Haematologica Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. 104(12):e555-e557 Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR
- Haematologica Molecular remissions are observed in chronic adult T-cell leukemia/lymphoma in patients treated with mogamulizumab. 104(12):e566-e569 Cook LBM, Demontis MA, Sagawe S, Witkover A, Melamed A, Turpin J, Dillon R, Haddow J, Marks AJ, Bangham CRM, Fields P, Taylor GP, Rowan AG
- J Clin Oncol Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. J Clin Oncol. 2019 Dec 27:JCO1900895. doi: 10.1200/JCO.19.00895. Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH Jr, Winton EF, Parker DR, Lee H, Reister A, Schultz, Savage S, Stevens, Brockett C, Subbiah N, Press RD, Raess PW, Cascio M, Dunlap J, Chen Y, Degnin C, Maxson JE, Tognon CE, Macey T, Druker BJ, Tyner JW
- J Clin Oncol Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. J Clin Oncol. 2019 Dec 20:JCO1903011. doi: 10.1200/JCO.19.03011. Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME
- J Clin Oncol Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J Clin Oncol. 2019 Dec 18:JCO1901406. doi: 10.1200/JCO.19.01406. Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Greil R, Hertenstein B, Krauter J, Martens U, Nachbaur D, Abu Samra M, Girschikofsky M, Basara N, Benner A, Thol F, Heuser M, Ganser A, Döhner K, Döhner H
- J Clin Oncol Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics. 37(36):3493-3506 Eckert C, Groeneveld-Krentz S, Kirschner-Schwabe R, Hagedorn N, Chen-Santel C, Bader P, Borkhardt A, Cario G, Escherich G, Panzer-Grümayer R, Astrahantseff K, Eggert A, Sramkova L, Attarbaschi A, Bourquin JP, Peters C, Henze G, von Stackelberg A; ALL-REZ BFM Trial Group
- J Clin Oncol Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0331. J Clin Oncol. 2019 Dec 11:JCO1901086. doi: 10.1200/JCO.19.01086. Maloney KW, Devidas M, Wang C, Mattano LA, Friedmann AM, Buckley P, Borowitz MJ, Carroll AJ, Gastier-Foster JM, Heerema NA, Kadan-Lottick N, Loh ML, Matloub YH, Marshall DT, Stork LC, Raetz EA, Wood B, Hunger SP, Carroll WL, Winick NJ
- J Clin Oncol Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. J Clin Oncol. 2019 Dec 9:JCO1901892. doi: 10.1200/JCO.19.01892. Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL
- J Clin Oncol Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. J Clin Oncol. 2019 Dec 3:JCO1901053. doi: 10.1200/JCO.19.01053. Lübbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt M, Heuser M, Thol F, Salih HR, Schittenhelm MM, Germing U, Kuendgen A, Götze KS, Lindemann HW, Müller-Tidow C, Heil G, Scholl S, Bug G, Schwaenen C, Giagounidis A, Neubauer A, Krauter J, Brugger W, De Wit M, Wäsch R, Becker H, May AM, Duyster J, Döhner K, Ganser A, Hackanson B, Döhner H; DECIDER Study Team
- J Clin Oncol Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. 37(35):3377-3391 Jeha S, Pei D, Choi J, Cheng C, Sandlund JT, Coustan-Smith E, Campana D, Inaba H, Rubnitz JE, Ribeiro RC, Gruber TA, Raimondi SC, Khan RB, Yang JJ, Mullighan CG, Downing JR, Evans WE, Relling MV, Pui CH
- Lancet Haematol Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study. Lancet Haematol. 2019 Dec 23. pii: S2352-3026(19)30206-6. doi: 10.1016/S2352-3026(19)30206-6. Myers KC, Furutani E, Weller E, Siegele B, Galvin A, Arsenault V, Alter BP, Boulad F, Bueso-Ramos C, Burroughs L, Castillo P, Connelly J, Davies SM, DiNardo CD, Hanif I, Ho RH, Karras N, Manalang M, McReynolds LJ, Nakano TA, Nalepa G, Norkin M, Oberley MJ, Orgel E, Pastore YD, Rosenthal J, Walkovich K, Larson J, Malsch M, Elghetany MT, Fleming MD, Shimamura A
- Lancet Haematol Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2019 Dec 11. pii: S2352-3026(19)30203-0. doi: 10.1016/S2352-3026(19)30203-0. Brunner AM, Blonquist TM, DeAngelo DJ, McMasters M, Fell G, Hermance NM, Winer ES, Lindsley RC, Hobbs GS, Amrein PC, Hock HR, Steensma DP, Garcia JS, Luskin MR, Stone RM, Ballen KK, Rosenblatt J, Avigan D, Nahas MR, Mendez LM, McAfee SL, Moran JA, Bergeron M, Foster J, Bertoli C, Manning AL, McGregor KL, Fishman KM, Kuo FC, Baltay MT, Macrae M, Burke M, Behnan T, Wey MC, Som TT, Ramos AY, Rae J, Lombardi Story J, Nelson N, Logan E, Connolly C, Neuberg DS, Chen YB, Graubert TA, Fathi AT
- Lancet Haematol Alisertib: a new option for acute myeloid leukaemia. Lancet Haematol. 2019 Dec 11. pii: S2352-3026(19)30215-7. doi: 10.1016/S2352-3026(19)30215-7. Thomas X
- Lancet Oncol Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. 20(12):1710-1718 Laetsch TW, Myers GD, Baruchel A, Dietz AC, Pulsipher MA, Bittencourt H, Buechner J, De Moerloose B, Davis KL, Nemecek E, Driscoll T, Mechinaud F, Boissel N, Rives S, Bader P, Peters C, Sabnis HS, Grupp SA, Yanik GA, Hiramatsu H, Stefanski HE, Rasouliyan L, Yi L, Shah S, Zhang J, Harris AC
- Leukemia Do persons with chronic myeloid leukaemia have normal or near normal survival? Leukemia. 2019 Dec 20. doi: 10.1038/s41375-019-0699-y. Radivoyevitch T, Weaver D, Hobbs B, Maciejewski JP, Hehlmann R, Jiang Q, Hochhaus A, Gale RP
- Leukemia The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia. 2019 Dec 20. doi: 10.1038/s41375-019-0682-7. Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA
- Leukemia Quantitative distribution of patient-derived leukemia clones in murine xenografts revealed by cellular barcodes. Leukemia. 2019 Dec 18. doi: 10.1038/s41375-019-0695-2. Jacobs S, Ausema A, Zwart E, Weersing E, Kingma MJ, El Menshawi YAS, de Haan G, Bystrykh LV, Belderbos ME
- Leukemia Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia. Leukemia. 2019 Dec 17. doi: 10.1038/s41375-019-0683-6. Somers K, Evans K, Cheung L, Karsa M, Pritchard T, Kosciolek A, Bongers A, El-Ayoubi A, Forgham H, Middlemiss S, Mayoh C, Jones L, Gupta M, Kees UR, Chernova O, Korotchkina L, Gudkov AV, Erickson SW, Teicher B, Smith MA, Norris MD, Haber M, Lock RB, Henderson MJ
- Leukemia Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy. Leukemia. 2019 Dec 16. doi: 10.1038/s41375-019-0688-1. Stoner RC, Press RD, Maxson JE, Tyner JW, Dao KT
- Leukemia Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. Leukemia. 2019 Dec 13. doi: 10.1038/s41375-019-0690-7. Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R, Gangat N, Binder M, Pardanani A, Fernandez-Zapico M, Robertson KD, Bosi A, Droin N, Vannucchi AM, Tefferi A, Hunter A, Padron E, Solary E, Patnaik MM
- Leukemia SHP1 regulates a STAT6-ITGB3 axis in FLT3ITD-positive AML cells. Leukemia. 2019 Dec 13. doi: 10.1038/s41375-019-0676-5. Reich D, Kresinsky A, Müller JP, Bauer R, Kallenbach J, Schnoeder TM, Heidel FH, Fässler R, Mann M, Böhmer FD, Jayavelu AK
- Leukemia Molecular-defined clonal evolution in patients with chronic myeloid leukemia who were exposed to ionizing radiation following the Chernobyl nuclear disaster. Leukemia. 2019 Dec 13. doi: 10.1038/s41375-019-0679-2. Ernst T, Rinke J, Hagen J, Dmytrenko I, Hochhaus A, Dyagil I
- Leukemia Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2019 Dec 12. doi: 10.1038/s41375-019-0686-3. Yu S, Huang F, Wang Y, Xu Y, Yang T, Fan Z, Lin R, Xu N, Xuan L, Ye J, Yu W, Sun J, Huang X, Liu Q
- Leukemia NPM1c impedes CTCF functions through cytoplasmic mislocalization in acute myeloid leukemia. Leukemia. 2019 Dec 12. doi: 10.1038/s41375-019-0681-8. Wang AJ, Han Y, Jia N, Chen P, Minden MD
- Leukemia Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. Leukemia. 2019 Dec 5. doi: 10.1038/s41375-019-0670-y. Attarbaschi A, Mann G, Zimmermann M, Bader P, Barisone E, Basso G, Biondi A, Cario G, Cazzaniga G, Colombini A, Flotho C, Kuhlen M, Lang P, Lauten M, Linderkamp C, Locatelli F, Lo Nigro L, Möricke A, Niggli F, Panzer-Grümayer R, Parasole R, Peters C, Caterina Putti M, Rizzari C, Suttorp M, Valsecchi MG, Conter V, Schrappe M; on behalf of the AIEOP-BFM (Associazione Italiana di Ematologia e Oncologia Pediatrica & Berlin-Frankfurt-Münster) Study Group
- Leukemia Unexpected variation in leukemia stem cell frequency and genetic heterogeneity in two murine leukemia models initiated by AML1/ETO9a and CALM/AF10. Leukemia. 2019 Dec 4. doi: 10.1038/s41375-019-0657-8. Desai R, Taghavi S, Chase JC, Chopra M, Chien J, Browett PJ, Kakadia PM, Bohlander SK
- Leukemia Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia. 2019 Dec 3. doi: 10.1038/s41375-019-0645-z. Kubasch AS, Schulze F, Giagounidis A, Götze KS, Krönke J, Sockel K, Middeke JM, Chermat F, Gloaguen S, Puttrich M, Weigt C, William D, Fenaux P, Schlenk RF, Thiede C, Stasik S, Mies A, Adès L, Oelschlägel U, Platzbecker U
- Leukemia Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. Leukemia. 2019 Dec 3. doi: 10.1038/s41375-019-0671-x. Morsink LM, Bezerra ED, Othus M, Wood BL, Fang M, Sandmaier BM, Mielcarek MB, Deeg HJ, Schoch G, Appelbaum FR, Walter RB
- Leukemia CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. 33(12):2767-2778 Mohty M, Gautier J, Malard F, Aljurf M, Bazarbachi A, Chabannon C, Kharfan-Dabaja MA, Savani BN, Huang H, Kenderian S, Nagler A, Perales MA
- Leukemia How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. 33(12):2795-2804 Jonas BA, Pollyea DA
- Leukemia Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. 33(12):2805-2816 Nii T, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Nishida Y, Kojima K, Garnett MJ, McDermott U, Benes CH, Charter N, Deacon S, Elemento O, Allen JE, Oster W, Stogniew M, Ishizawa J, Andreeff M
- Leukemia The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia. 33(12):2817-2829 Armenteros-Monterroso E, Zhao L, Gasparoli L, Brooks T, Pearce K, Mansour MR, Martens JHA, de Boer J, Williams O
- Leukemia The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. 33(12):2830-2841 Angenendt L, Bormann E, Pabst C, Alla V, Görlich D, Braun L, Dohlich K, Schwöppe C, Bohlander SK, Arteaga MF, Wethmar K, Hartmann W, Angenendt A, Kessler T, Mesters RM, Stelljes M, Rothenberg-Thurley M, Spiekermann K, Hébert J, Sauvageau G, Valk PJM, Löwenberg B, Serve H, Müller-Tidow C, Lenz G, Wörmann BJ, Sauerland MC, Hiddemann W, Berdel WE, Krug U, Metzeler KH, Mikesch JH, Herold T, Schliemann C
- Leukemia CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. 33(12):2854-2866 Pan J, Niu Q, Deng B, Liu S, Wu T, Gao Z, Liu Z, Zhang Y, Qu X, Zhang Y, Liu S, Ling Z, Lin Y, Zhao Y, Song Y, Tan X, Zhang Y, Li Z, Yin Z, Chen B, Yu X, Yan J, Zheng Q, Zhou X, Gao J, Chang AH, Feng X, Tong C
- Leukemia Risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia after childhood cancer: a population-based study. 33(12):2947-2978 Advani PG, Schonfeld SJ, Curtis RE, Dores GM, Linet MS, Sigel BS, Lam CJK, Tucker MA, Chanock SJ, Morton LM
- Leukemia Diminished interaction between mutant NOTCH1 and the NuRD corepressor complex upregulates CCL17 in chronic lymphocytic leukemia. 33(12):2951-2956 Wang S, Ge M, Cui J, Qiao Z, Chen X, Wu S, Zhan R, Zhou H, Liu H, Xu Z
- N Engl J Med Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. 381(24):2315-2326 Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW
Lymphoma
- Blood Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma. Blood. 2019 Dec 3. pii: blood.2019001866. doi: 10.1182/blood.2019001866. Bucher P, Erdmann T, Grondona P, Xu W, Schmitt A, Schürch C, Zapukhlyak M, Schönfeld C, Serfling E, Kramer D, Grau M, Klener P, Lengerke C, Schulze-Osthoff K, Lenz G, Hailfinger S
- Blood The Immune Landscape and Response to Immune Checkpoint Blockade Therapy in Lymphoma. Blood. 2019 Dec 2. pii: blood.2019000847. doi: 10.1182/blood.2019000847. Kline J, Godfrey J, Ansell SM
- Blood Subclassifying peripheral T-cell lymphoma NOS. 134(24):2120-2121 Carbone A, Gloghini A
- Blood Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. 134(24):2159-2170 Amador C, Greiner TC, Heavican TB, Smith LM, Galvis KT, Lone W, Bouska A, D'Amore F, Pedersen MB, Pileri S, Agostinelli C, Feldman AL, Rosenwald A, Ott G, Mottok A, Savage KJ, de Leval L, Gaulard P, Lim ST, Ong CK, Ondrejka SL, Song J, Campo E, Jaffe ES, Staudt LM, Rimsza LM, Vose J, Weisenburger DD, Chan WC, Iqbal J
- Blood Constipated plasma cells in extranodal marginal zone lymphoma of the lung. 134(24):2226 Cheng J, Jaffe ES
- Blood The EZ-riding NK/T-cell lymphoma. 134(23):1999-2000 Johnson WT, Mishra A
- Blood MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma. 134(23):2046-2058 Li B, Yan J, Phyu T, Fan S, Chung TH, Mustafa N, Lin B, Wang L, Eichhorn PJA, Goh BC, Ng SB, Kappei D, Chng WJ
- Blood The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative. 134(23):2059-2069 Patel SS, Weirather JL, Lipschitz M, Lako A, Chen PH, Griffin GK, Armand P, Shipp MA, Rodig SJ
- Br J Haematol What do we know about duodenal-type follicular lymphoma? From pathological definition to treatment options. Br J Haematol. 2019 Dec 27. doi: 10.1111/bjh.16348. Duffles Amarante G, Collins G, Rocha V
- Br J Haematol Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). Br J Haematol. 2019 Dec 27. doi: 10.1111/bjh.16255. Pettengell R, Długosz-Danecka M, Andorsky D, Belada D, Georgiev P, Quick D, Singer JW, Singh SB, Pallis A, Egorov A, Salles G
- Br J Haematol Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma. Br J Haematol. 2019 Dec 17. doi: 10.1111/bjh.16302. Rodgers TD, Baran A, Reagan PM, Casulo C, Zent C, Evans A, Burack R, Williams AM, Friedberg JW, Barr PM
- Br J Haematol Validation of a simplified international prognostic score (IPS-3) in patients with advanced-stage classic Hodgkin lymphoma. Br J Haematol. 2019 Dec 10. doi: 10.1111/bjh.16293. Hayden AR, Lee DG, Villa D, Gerrie AS, Scott DW, Slack GW, Sehn LH, Connors JM, Savage KJ
- Br J Haematol Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting. Br J Haematol. 2019 Dec 7. doi: 10.1111/bjh.16289. Korula A, Devasia AJ, Kulkarni U, Abubacker FN, Lakshmi KM, Abraham A, Srivastava A, George B, Mathews V
- Br J Haematol Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. Br J Haematol. 2019 Dec 5. doi: 10.1111/bjh.16319. Landsburg DJ, Ayers EC, Bond DA, Maddocks KJ, Karmali R, Behdad A, Curry M, Wagner-Johnston ND, Modi D, Ramchandren R, Assouline SE, Faramand R, Chavez JC, Torka P, Mier Hicks A, Medeiros LJ, Li S
- Br J Haematol First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. Br J Haematol. 2019 Dec 2. doi: 10.1111/bjh.16264. Walewski J, Paszkiewicz-Kozik E, Michalski W, Rymkiewicz G, Szpila T, Butrym A, Giza A, Zaucha JM, Kalinka-Warzocha E, Wieczorkiewicz A, Zimowska-Curyło D, Knopińska-Posłuszny W, Tyczyńska A, Romejko-Jarosińska J, Dąbrowska-Iwanicka A, Gruszecka B, Jamrozek-Jedlińska M, Borawska A, Hołda W, Porowska A, Romanowicz A, Hellmann A, Stella-Hołowiecka B, Deptała A, Jurczak W
- Br J Haematol Extracavitary primary effusion lymphoma in a post-transplantation patient. 187(5):555 Zanelli M, Bertuzzi C, Zizzo M, Martino G, Sabattini E, Ascani S
- Br J Haematol Closing the survivorship gap in children and adolescents with Hodgkin lymphoma. 187(5):573-587 Castellino SM, Parsons SK, Kelly KM
- Br J Haematol Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas. 187(5):595-601 Spriano F, Tarantelli C, Gaudio E, Gerlach MM, Priebe V, Cascione L, Bernasconi E, Targa A, Mascia M, Dirnhofer S, Stathis A, Zucca E, Bertoni F
- Br J Haematol The impact of SOCS1 mutations in diffuse large B-cell lymphoma. 187(5):627-637 Mellert K, Martin M, Lennerz JK, Lüdeke M, Staiger AM, Kreuz M, Löffler M, Schmitz N, Trümper L, Feller AC, Hartmann S, Hansmann ML, Klapper W, Stein H, Rosenwald A, Ott G, Ziepert M, Möller P
- Haematologica Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. Haematologica. 2019 Dec 19. pii: haematol.2019.238162. doi: 10.3324/haematol.2019.238162. Chamuleau MED, Burggraaff CN, Nijland M, Bakunina K, Mous R, Lugtenburg PJ, Dierickx D, van Imhoff GW, Vermaat JSP, Marijt EAF, Visser O, Mandigers C, Bilgin YM, Beeker A, Durian MF, van Rees B, Bohmer LH, Tick LW, Boersma RS, Snijders TJF, Schouten HC, Koene HR, de Jongh E, Hijmering N, Diepstra A, van den Berg A, Arens AIJ, Huijbregts J, Hoekstra O, Zijlstra JM, de Jong D, Kersten MJ
- Haematologica MYD88 in the driver’s seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications. 104(12):2337-2348 de Groen RAL, Schrader AMR, Kersten MJ, Pals ST, Vermaat JSP
- Haematologica Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. 104(12):e558-e561 Cascione L, Rinaldi A, Bruscaggin A, Tarantelli C, Arribas AJ, Kwee I, Pecciarini L, Mensah AA, Spina V, Chung EYL, di Bergamo LT, Dirnhofer S, Tzankov A, Miranda RN, Young KH, Traverse-Glehen A, Gaidano G, Swerdlow SH, Gascoyne R, Rabadan R, Ponzoni M, Bhagat G, Rossi D, Zucca E, Bertoni F
- Haematologica ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. 104(12):e562-e565 Sibon D, Nguyen DP, Schmitz N, Suzuki R, Feldman AL, Gressin R, Lamant L, Weisenburger DD, Rosenwald A, Nakamura S, Ziepert M, Maurer MJ, Bast M, Armitage JO, Vose JM, Tilly H, Jais JP, Savage KJ
- Haematologica Molecular remissions are observed in chronic adult T-cell leukemia/lymphoma in patients treated with mogamulizumab. 104(12):e566-e569 Cook LBM, Demontis MA, Sagawe S, Witkover A, Melamed A, Turpin J, Dillon R, Haddow J, Marks AJ, Bangham CRM, Fields P, Taylor GP, Rowan AG
- J Clin Oncol Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma. 37(36):3528-3537 Borchmann S, Cirillo M, Goergen H, Meder L, Sasse S, Kreissl S, Bröckelmann PJ, von Tresckow B, Fuchs M, Ullrich RT, Engert A
- J Clin Oncol Immune Infiltration and the Potential for a Biology-Guided Approach to Follicular Lymphoma. J Clin Oncol. 2019 Dec 9:JCO1902398. doi: 10.1200/JCO.19.02398. Sorigue M
- J Clin Oncol Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol. 2019 Dec 5:JCO1901294. doi: 10.1200/JCO.19.01294. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, Stilgenbauer S, Kaiser F, Doorduijn JK, Salles G, Szymczyk M, Tilly H, Kanz L, Schmidt C, Feugier P, Thieblemont C, Zijlstra JM, Ribrag V, Klapper W, Pott C, Unterhalt M, Dreyling MH
- J Clin Oncol Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. 37(35):3359-3368 Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, de Jong D, Sehn LH, Maucort-Boulch D
- J Clin Oncol Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. 37(34):3291-3299 Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, Özcan M, Portino S, Fogliatto L, Caballero MD, Walewski J, Gulbas Z, Ribrag V, Christian B, Perini GF, Salles G, Svoboda J, Zain J, Patel S, Chen PH, Ligon AH, Ouyang J, Neuberg D, Redd R, Chatterjee A, Balakumaran A, Orlowski R, Shipp M, Zinzani PL
- J Clin Oncol Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration. 37(34):3300-3309 Tobin JWD, Keane C, Gunawardana J, Mollee P, Birch S, Hoang T, Lee J, Li L, Huang L, Murigneux V, Fink JL, Matigian N, Vari F, Francis S, Kridel R, Weigert O, Haebe S, Jurinovic V, Klapper W, Steidl C, Sehn LH, Law SC, Wykes MN, Gandhi MK
- Lancet Chemoimmunotherapy for localised low-risk diffuse large B-cell lymphoma. 394(10216):2208-2209 Vose JM
- Lancet Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. 394(10216):2271-2281 Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance
- Lancet Oncol Genetic susceptibility to natural killer T-cell lymphoma. Lancet Oncol. 2019 Dec 23. pii: S1470-2045(19)30820-4. doi: 10.1016/S1470-2045(19)30820-4. Küçük C
- Lancet Oncol Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol. 2019 Dec 23. pii: S1470-2045(19)30799-5. doi: 10.1016/S1470-2045(19)30799-5. Lin GW, Xu C, Chen K, Huang HQ, Chen J, Song B, Chan JKC, Li W, Liu W, Shih LY, Chuang WY, Kim WS, Tan W, Peng RJ, Laurensia Y, Cheah DMZ, Huang D, Cheng CL, Su YJ, Tan SY, Ng SB, Tang TPL, Han K, Wang VY, Jia WH, Pei Z, Li YJ, Gao S, Shi Y, Hu Z, Zhang F, Zhang B, Zeng YX, Shen H, He L, Ong CK, Lim ST, Chanock S, Kwong YL, Lin D, Rothman N, Khor CC, Lan Q, Bei JX; International NKTCL Working Group
- Lancet Oncol Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2019 Dec 4. pii: S1470-2045(19)30671-0. doi: 10.1016/S1470-2045(19)30671-0. Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
- Leukemia The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. Leukemia. 2019 Dec 13. doi: 10.1038/s41375-019-0677-4. Pichard A, Marcatili S, Karam J, Constanzo J, Ladjohounlou R, Courteau A, Jarlier M, Bonnefoy N, Patzke S, Stenberg V, Coopman P, Cartron G, Navarro-Teulon I, Repetto-Llamazares A, Heyerdahl H, Dahle J, Bardiès M, Pouget JP
- Leukemia Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). Leukemia. 2019 Dec 11. doi: 10.1038/s41375-019-0658-7. Rule SA, Cartron G, Fegan C, Morschhauser F, Han L, Mitra S, Salles G, Dyer MJS
- Leukemia CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. 33(12):2767-2778 Mohty M, Gautier J, Malard F, Aljurf M, Bazarbachi A, Chabannon C, Kharfan-Dabaja MA, Savani BN, Huang H, Kenderian S, Nagler A, Perales MA
- Leukemia Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. 33(12):2867-2883 Watatani Y, Sato Y, Miyoshi H, Sakamoto K, Nishida K, Gion Y, Nagata Y, Shiraishi Y, Chiba K, Tanaka H, Zhao L, Ochi Y, Takeuchi Y, Takeda J, Ueno H, Kogure Y, Shiozawa Y, Kakiuchi N, Yoshizato T, Nakagawa MM, Nanya Y, Yoshida K, Makishima H, Sanada M, Sakata-Yanagimoto M, Chiba S, Matsuoka R, Noguchi M, Hiramoto N, Ishikawa T, Kitagawa J, Nakamura N, Tsurumi H, Miyazaki T, Kito Y, Miyano S, Shimoda K, Takeuchi K, Ohshima K, Yoshino T, Ogawa S, Kataoka K
- Leukemia Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma. 33(12):2884-2897 Lupino L, Perry T, Margielewska S, Hollows R, Ibrahim M, Care M, Allegood J, Tooze R, Sabbadini R, Reynolds G, Bicknell R, Rudzki Z, Lin Hock Y, Zanetto U, Wei W, Simmons W, Spiegel S, Woodman CBJ, Rowe M, Vrzalikova K, Murray PG
- Leukemia PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells. 33(12):2898-2911 Zhu F, Guo H, Bates PD, Zhang S, Zhang H, Nomie KJ, Li Y, Lu L, Seibold KR, Wang F, Rumball I, Cameron H, Hoang NM, Yang DT, Xu W, Zhang L, Wang M, Capitini CM, Rui L
- Leukemia Disruption of the Myc-PDE4B regulatory circuitry impairs B-cell lymphoma survival. 33(12):2912-2923 Nam J, Kim DU, Kim E, Kwak B, Ko MJ, Oh AY, Park BJ, Kim YW, Kim A, Sun H, Jung Y, Lee JH, Shin HJ, Park I, Song DK, Jeong JY, Lee YH, Kim SW
Myeloma
- Blood Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. 134(24):2218-2222 Sanoja-Flores L, Flores-Montero J, Puig N, Contreras-Sanfeliciano T, Pontes R, Corral-Mateos A, García-Sánchez O, Díez-Campelo M, Pessoa de Magalhães RJ, García-Martín L, Alonso-Alonso JM, García-Mateo A, Aguilar-Franco C, Labrador J, Barez-García A, Maiolino A, Paiva B, San Miguel J, Sobral da Costa E, González M, Mateos MV, Durie B, van Dongen JJM, Orfao A
- Br J Haematol Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. Br J Haematol. 2019 Dec 9. doi: 10.1111/bjh.16292. Mohan M, Weinhold N, Schinke C, Thanedrarajan S, Rasche L, Sawyer JR, Tian E, van Rhee F, Zangari M
- Br J Haematol Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience. Br J Haematol. 2019 Dec 2. doi: 10.1111/bjh.16324. Djebbari F, Hubenov H, Neelakantan P, Wolf J, Offer M, Khera A, Louka E, Vallance G, Kothari J, Moore S, Ramasamy K
- Br J Haematol Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study. Br J Haematol. 2019 Dec 2. doi: 10.1111/bjh.16286. Cejalvo MJ, Legarda M, Abella E, Cabezudo E, Encinas C, García-Feria A, Gironella M, Iñigo B, Martín J, Ribas P, Ruíz MÁ, González Y, Vicuña I, Ramírez Á, Fernández P, de la Rubia J
- Br J Haematol Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry. 187(5):602-614 Terebelo HR, Abonour R, Gasparetto CJ, Toomey K, Durie BGM, Hardin JW, Jagannath S, Wagner L, Narang M, Flick ED, Srinivasan S, Yue L, Kitali A, Agarwal A, Rifkin RM; CONNECT MM Registry Investigators
- Haematologica Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. Haematologica. 2019 Dec 19. pii: haematol.2019.236588. doi: 10.3324/haematol.2019.236588. Corre J, Montes L, Martin E, Perrot A, Caillot D, Leleu X, Belhadj K, Facon T, Hulin C, Mohty M, Fontan J, Macro M, Brechignac S, Jaccard A, Stoppa AM, Orsini-Piocelle F, Adiko D, Voillat L, Keddar F, Barry M, Demarquette H, Certain MN, Plantier I, Roussel M, Hébraud B, Filleron T, Attal M, Avet-Loiseau H
- Haematologica Fractures and survival in multiple myeloma: results from a population-based study. Haematologica. 2019 Dec 2. pii: haematol.2019.230011. doi: 10.3324/haematol.2019.230011. Thorsteinsdottir S, Gislason G, Aspelund T, Sverrisdottir I, Landgren O, Turesson I, Björkholm M, Kristinsson SY
- Haematologica Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. 104(12):2358-2360 Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Bladé J, Delforge M, Hajek R, Ludwig H, Facon T, Miguel JFS, Einsele H
- Haematologica Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples. 104(12):2456-2464 Späth F, Wibom C, Krop EJM, Santamaria AI, Johansson AS, Bergdahl IA, Hultdin J, Vermeulen R, Melin B
- Haematologica Functional interplay between NF-κB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma. 104(12):2465-2481 Mazzera L, Abeltino M, Lombardi G, Cantoni AM, Ria R, Ricca M, Saltarella I, Naponelli V, Rizzi FMA, Perris R, Corradi A, Vacca A, Bonati A, Lunghi P
- Lancet Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2019 Dec 10. pii: S0140-6736(19)32956-3. doi: 10.1016/S0140-6736(19)32956-3. Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J
- Lancet Quadruplets come of age for newly diagnosed multiple myeloma. Lancet. 2019 Dec 10. pii: S0140-6736(19)33063-6. doi: 10.1016/S0140-6736(19)33063-6. Bhutani M, Usmani SZ
- Lancet Incorporating isatuximab in the treatment of multiple myeloma. 394(10214):2045-2047 Trudel S
- Lancet Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. 394(10214):2096-2107 Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group
- Lancet Haematol Frontline therapy in multiple myeloma: fast start for a long game. 6(12):e600-e601 Patriarca F
- Lancet Haematol Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. 6(12):e616-e629 Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Waterhouse A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Wilson JN, Jenner MW, Cook G, Kaiser MF, Drayson MT, Owen RG, Russell NH, Gregory WM, Morgan GJ; UK NCRI Haematological Oncology Clinical Studies Group
- Lancet Oncol Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2019 Dec 16. pii: S1470-2045(19)30788-0. doi: 10.1016/S1470-2045(19)30788-0. Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD
- Lancet Oncol Reducing infection-related morbidity and mortality in patients with myeloma. 20(12):1633-1635 Ramasamy K
- Lancet Oncol Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. 20(12):1760-1772 Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, Wood J, Raynes K, Higgins H, Dawkins B, Meads D, Hulme CT, Monahan I, Karunanithi K, Dignum H, Belsham E, Neilson J, Harrison B, Lokare A, Campbell G, Hamblin M, Hawkey P, Whittaker AC, Low E, Dunn JA; TEAMM Trial Management Group and Trial Investigators
- Lancet Oncol Early intervention effective in smouldering multiple myeloma. 20(12):e666 Gourd E
- Leukemia Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma. Leukemia. 2019 Dec 13. doi: 10.1038/s41375-019-0689-0. Maura F, Rustad EH, Yellapantula V, Łuksza M, Hoyos D, Maclachlan KH, Diamond BT, Greenbaum BD, Morgan G, Lesokhin A, Papaemmanuil E, Landgren O
- Leukemia The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. 33(12):2924-2933 Raab MS, Thomas SK, Ocio EM, Guenther A, Goh YT, Talpaz M, Hohmann N, Zhao S, Xiang F, Simon C, Vanasse KG, Kumar SK
SCT
- Blood How I treat sickle cell disease with hematopoietic cell transplantation. 134(25):2249-2260 Stenger EO, Shenoy S, Krishnamurti L
- Blood Is There an Optimal Conditioning for Older Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation? Blood. 2019 Dec 11. pii: blood.2019003662. doi: 10.1182/blood.2019003662. Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta RS, Oran B, Popat U, Hosing C, Olson A, Daver N, Konopleva M, Champlin R
- Blood Romiplostim in Patients undergoing Hematopoietic Stem Cell Transplantation: Results of a Phase I/II multicenter Trial. Blood. 2019 Dec 5. pii: blood.2019000358. doi: 10.1182/blood.2019000358. Peffault de Latour R, Chevret S, Ruggeri AL, Suarez F, Souchet L, Michonneau D, Sicre de Fontbrune F, Coman T, Dhedin N, Rubio MT, Nguyen S, Mohty M, Socié G
- Br J Haematol Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). Br J Haematol. 2019 Dec 27. doi: 10.1111/bjh.16255. Pettengell R, Długosz-Danecka M, Andorsky D, Belada D, Georgiev P, Quick D, Singer JW, Singh SB, Pallis A, Egorov A, Salles G
- Br J Haematol Post-chimeric antigen receptor T-cell therapy haematopoietic stem cell transplantation for 52 cases with refractory/relapsed B-cell acute lymphoblastic leukaemia. Br J Haematol. 2019 Dec 23. doi: 10.1111/bjh.16339. Zhang Y, Chen H, Song Y, Tan X, Zhao Y, Liu X, Li Z, Yang F, Jiang M, Gao Z, Wu T
- Br J Haematol The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol. 2019 Dec 10. doi: 10.1111/bjh.16355. Loke J, Malladi R, Moss P, Craddock C
- Br J Haematol A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom. 187(5):642-652 Sharpley FA, Petrie A, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Fontana M, Martinez-Naharro A, Quarta C, Hawkins PN, Wechalekar AD
- Haematologica Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. Haematologica. 2019 Dec 26. pii: haematol.2019.229252. doi: 10.3324/haematol.2019.229252. Wagner-Drouet E, Teschner D, Wolschke C, Janson D, Schäfer-Eckart K, Gärtner J, Mielke S, Schreder M, Kobbe G, Kondakci M, Hilgendorf I, von Lilienfeld-Toal M, Klein S, Heidenreich D, Kreil S, Verbeek M, Graß S, Ditschkowski M, Gromke T, Koch M, Lindemann M, Hünig T, Schmidt T, Rascle A, Guldan H, Barabas S, Deml L, Wagner R, Wolff D
- Haematologica Focusing of the regulatory T-cell repertoire after allogeneic stem cell transplantation indicates protection from graft-versus-host disease. 104(12):e577-e580 Odak I, Raha S, Schultze-Florey C, Tavil S, Ravens S, Ganser A, Förster R, Prinz I, Koenecke C
HSC
- Blood Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells. 134(26):2383-2387 Mansier O, Kilani B, Guitart AV, Guy A, Gourdou-Latyszenok V, Marty C, Parrens M, Plo I, Vainchenker W, James C
- Blood Romiplostim in Patients undergoing Hematopoietic Stem Cell Transplantation: Results of a Phase I/II multicenter Trial. Blood. 2019 Dec 5. pii: blood.2019000358. doi: 10.1182/blood.2019000358. Peffault de Latour R, Chevret S, Ruggeri AL, Suarez F, Souchet L, Michonneau D, Sicre de Fontbrune F, Coman T, Dhedin N, Rubio MT, Nguyen S, Mohty M, Socié G
- Br J Haematol Post-chimeric antigen receptor T-cell therapy haematopoietic stem cell transplantation for 52 cases with refractory/relapsed B-cell acute lymphoblastic leukaemia. Br J Haematol. 2019 Dec 23. doi: 10.1111/bjh.16339. Zhang Y, Chen H, Song Y, Tan X, Zhao Y, Liu X, Li Z, Yang F, Jiang M, Gao Z, Wu T
- Haematologica Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. Haematologica. 2019 Dec 26. pii: haematol.2019.229252. doi: 10.3324/haematol.2019.229252. Wagner-Drouet E, Teschner D, Wolschke C, Janson D, Schäfer-Eckart K, Gärtner J, Mielke S, Schreder M, Kobbe G, Kondakci M, Hilgendorf I, von Lilienfeld-Toal M, Klein S, Heidenreich D, Kreil S, Verbeek M, Graß S, Ditschkowski M, Gromke T, Koch M, Lindemann M, Hünig T, Schmidt T, Rascle A, Guldan H, Barabas S, Deml L, Wagner R, Wolff D
- Haematologica Humanized zebrafish enhance human hematopoietic stem cell survival and promote acute myeloid leukemia clonal diversity. Haematologica. 2019 Dec 19. pii: haematol.2019.223040. doi: 10.3324/haematol.2019.223040. Rajan V, Melong N, Wong WH, King B, Tong RS, Mahajan N, Gaston D, Lund T, Rittenberg D, Dellaire G, Campbell CJV, Druley T, Berman JN
- Haematologica Microenvironmental contributions to hematopoietic stem cell aging. Haematologica. 2019 Dec 5. pii: haematol.2018.211334. doi: 10.3324/haematol.2018.211334. Ho YH, Méndez-Ferrer S
- Haematologica Understanding intrinsic hematopoietic stem cells aging. Haematologica. 2019 Dec 5. pii: haematol.2018.211342. doi: 10.3324/haematol.2018.211342. Mejia-Ramirez E, Florian MC
- Leukemia Phorbol ester induced ex vivo expansion of rigorously-defined phenotypic but not functional human cord blood hematopoietic stem cells: a cautionary tale demonstrating that phenotype does not always recapitulate stem cell function. 33(12):2962-2966 Chen Y, Yao C, Teng Y, Jiang R, Huang X, Liu S, Wan J, Broxmeyer HE, Guo B
Anemia
- Br J Haematol Haemolytic anaemia: an unrecognised side effect of hydroxyurea? Br J Haematol. 2019 Dec 25. doi: 10.1111/bjh.16346. Cornelisse AC, Bergkamp FJM, Griffioen-Keijzer A
- Haematologica Genetic disarray follows mutant KLF1-E325K expression in a congenital dyserythropoietic anemia patient. 104(12):2372-2380 Varricchio L, Planutis A, Manwani D, Jaffray J, Mitchell WB, Migliaccio AR, Bieker JJ
Bone marrow failure
- このキーワードに関連した論文はありません
ITP
- Br J Haematol Increased cytotoxic potential of CD8+ T cells in immune thrombocytopenia. Br J Haematol. 2019 Dec 18. doi: 10.1111/bjh.16334. Vrbensky JR, Arnold DM, Kelton JG, Smith JW, Jaffer AM, Larché M, Clare R, Ivetic N, Nazy I
- Haematologica Long-term outcomes after splenectomy in children with immune thrombocytopenia: an update on the registry data from the Intercontinental Cooperative ITP Study Group. Haematologica. 2019 Dec 19. pii: haematol.2019.236737. doi: 10.3324/haematol.2019.236737. Avila ML, Amiri N, Pullenayegum E, Blanchette V, Imbach P, Kühne T; Intercontinental Cooperative ITP Study Group